Key Details
Annual ROE
2.16%Beta
-Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
Nov 10, 2023Recent annual earnings:
Mar 24, 2023Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
25 Sept '23 Morgan Stanley
Equal-Weight25 Sept '23 Alliance Global Partners
Buy18 Aug '23 Morgan Stanley
Overweight13 June '23 HC Wainwright & Co.
Buy16 May '23 Morgan Stanley
Overweight29 Mar '23 HC Wainwright & Co.
Buy27 Mar '23 HC Wainwright & Co.
Buy21 Mar '23 HC Wainwright & Co.
Buy15 Aug '22 Morgan Stanley
Overweight11 Aug '22 HC Wainwright & Co.
BuyScreeners with VACC included
No data
Market Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
Vaccitech doesn't have historical dividend data
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Similar stocks
Vaccitech to Present Positive Final Data at EASL Congress for Phase 1b/2 HBV002 Study in Adults with Chronic Hepatitis B
VACC
GlobeNewsWire21 June 2023
OXFORD, United Kingdom, June 21, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics for the treatment of autoimmunity, chronic infectious diseases and cancer, will present positive final data from the HBV002 clinical trial at the European Association for the Study of the Liver (EASL) Congress 2023 – The International Liver CongressTM taking place June 21-24 in Vienna, Austria. HBV002 (NCT04778904) is a Phase 1b/2a clinical trial of VTP-300 in adults with chronic Hepatitis B (CHB). The data will be presented as a poster at EASL on Saturday, June 24 (Poster ID: SAT-198), by Eleanor Barnes, Professor of Hepatology and Experimental Medicine at Oxford University.
FAQ
- What is the primary business of Vaccitech?
- What is the ticker symbol for Vaccitech?
- Does Vaccitech pay dividends?
- What sector is Vaccitech in?
- What industry is Vaccitech in?
- What country is Vaccitech based in?
- When did Vaccitech go public?
- Is Vaccitech in the S&P 500?
- Is Vaccitech in the NASDAQ 100?
- Is Vaccitech in the Dow Jones?
- When was Vaccitech's last earnings report?
- When does Vaccitech report earnings?
- Should I buy Vaccitech stock now?
What is the primary business of Vaccitech?
Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious and autoimmunity diseases, and cancers. The company's therapeutic programs include VTP-300, which is in Phase 2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1b/2 clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.
What is the ticker symbol for Vaccitech?
The ticker symbol for Vaccitech is NASDAQ:VACC
Does Vaccitech pay dividends?
No, Vaccitech does not pay dividends
What sector is Vaccitech in?
Vaccitech is in the Healthcare sector
What industry is Vaccitech in?
Vaccitech is in the Biotechnology industry
What country is Vaccitech based in?
Vaccitech is headquartered in United Kingdom
When did Vaccitech go public?
Vaccitech's initial public offering (IPO) was on 30 April 2021
Is Vaccitech in the S&P 500?
No, Vaccitech is not included in the S&P 500 index
Is Vaccitech in the NASDAQ 100?
No, Vaccitech is not included in the NASDAQ 100 index
Is Vaccitech in the Dow Jones?
No, Vaccitech is not included in the Dow Jones index
When was Vaccitech's last earnings report?
Vaccitech's most recent earnings report was on 10 November 2023
When does Vaccitech report earnings?
The date for Vaccitech's next earnings report has not been announced yet
Should I buy Vaccitech stock now?
As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions